Guardant Health, Inc.

Precision medicineHealthcare diagnosticsGenomic analysis

$163.64vs prev close▼-7.05(-4.13%)

$53.4052W Range$176.58

89% from low

+23.36 (+15.86%)Past 1M

Price

ARK Trade PatternPREMIUM

1M Trades

No trades in 1M

1M net buy

≈ 0 shares

Portfolio Weight

0.60%

1M 0.00%p

Holding ETFs

1 ETFs

ARKG

Price Effect (Sell)

Shares decreased, but price appreciation increased portfolio weight.

Shares -6.4% · Market value -9.5% · Weight 0.00%p

Trade Intensity

No trades in 1M

Trade Log

Date	Action	ETF	Shares	Close	Est. total
26.07.09	SELL	ARKG	16,105	$164.08	$2.6M
26.07.08	SELL	ARKG	6,344	$156.17	$990.7K
26.07.07	SELL	ARKG	5,602	$162.92	$912.7K
26.03.20	SELL	ARKG	9,621	$85.18	$819.5K
26.03.18	SELL	ARKG	11,757	$87.27	$1.0M
26.02.27	SELL	ARKG	27,334	$93.90	$2.6M
26.02.06	SELL	ARKG	7,097	$101.85	$722.8K
26.02.05	SELL	ARKG	7,676	$98.36	$755.0K
26.02.04	SELL	ARKG	42,317	$106.15	$4.5M
26.02.03	SELL	ARKG	4,439	$113.05	$501.8K
26.02.02	SELL	ARKG	51,765	$114.90	$5.9M
26.01.06	SELL	ARKG	17,613	$112.33	$2.0M
26.01.05	SELL	ARKG	7,228	$101.87	$736.3K
26.01.02	SELL	ARKG	4,231	$101.74	$430.5K
25.11.14	SELL	ARKG	3,473	$94.37	$327.7K

07.09SELL

16,105

ARKGClose$164.08Est. total$2.6M

07.08SELL

6,344

ARKGClose$156.17Est. total$990.7K

07.07SELL

5,602

ARKGClose$162.92Est. total$912.7K

03.20SELL

9,621

ARKGClose$85.18Est. total$819.5K

03.18SELL

11,757

ARKGClose$87.27Est. total$1.0M

02.27SELL

27,334

ARKGClose$93.90Est. total$2.6M

02.06SELL

7,097

ARKGClose$101.85Est. total$722.8K

02.05SELL

7,676

ARKGClose$98.36Est. total$755.0K

02.04SELL

42,317

ARKGClose$106.15Est. total$4.5M

02.03SELL

4,439

ARKGClose$113.05Est. total$501.8K

02.02SELL

51,765

ARKGClose$114.90Est. total$5.9M

01.06SELL

17,613

ARKGClose$112.33Est. total$2.0M

01.05SELL

7,228

ARKGClose$101.87Est. total$736.3K

01.02SELL

4,231

ARKGClose$101.74Est. total$430.5K

11.14SELL

3,473

ARKGClose$94.37Est. total$327.7K

1 / 6

Prices estimated from market closing prices on trade dates. Actual execution prices may differ. This is not investment advice.

Stock Timeline

Institutional Holders

2 Holding · 0 Sold · Q4 2025

Based on ARK ETF real-time + 13F quarterly filings

Cathie WoodARK Invest

LIVE

454,757

Portfolio Weight

0.6%

in ETF 4.47%

Est. Value

$74M

30D Net

-$4M

Ray DalioBridgewater Associates

Increased

28,291

Portfolio Weight

0.01%

Est. Value

$3M

vs Prev Quarter

+606% (4K→28K)

13F data may be delayed up to 90 days.

Market Context

Analyst Consensus

※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.

Overall Opinion

Strong Buy

Buy

Strong Sell

Analyst Targets

avg.

$194.29

vs Current ▲ +13.8% upside

Current$170.69

Low ~ High$105.00 ~ $225.00

Firm

Position

Price Target

Upside / Downside

Close Price

Action

Date

Piper Sandler

Overweight

$193.00

+13.07%

—

Maintain

2026-08-04

Stephens & Co.

Overweight

$195.00

+14.24%

—

Maintain

2026-08-04

Morgan Stanley

Overweight

$185.00

+8.38%

—

Maintain

2026-08-04

Stifel

Buy

$180.00

+5.45%

—

Maintain

2026-08-03

RBC Capital

Outperform

$200.00

+17.17%

—

Maintain

2026-07-31

1 / 4

Avg Target

$194.29

vs Current ▲ +13.8% upside

Strong Buy

25 analysts

Strong Buy 5Buy 19Strong Sell 1

Low $105.00

Current $170.69

High $225.00

Firm	Position	Target	Upside	Close	Action	Date
Piper Sandler	Overweight	$193.00	+13.07%	—	Maintain	26.08.04
Stephens & Co.	Overweight	$195.00	+14.24%	—	Maintain	26.08.04
Morgan Stanley	Overweight	$185.00	+8.38%	—	Maintain	26.08.04
Stifel	Buy	$180.00	+5.45%	—	Maintain	26.08.03
RBC Capital	Outperform	$200.00	+17.17%	—	Maintain	26.07.31

1 / 4

Price Information

Previous Close$167.88

Open$167.21

Day Range$165.01 - $170.83

52-Week Range$53.40 - $176.58

1-Year Change175.84%

Trading Volume

Volume1,913,976

Avg Volume (3mo)2,658,150

Valuation

Market Cap22.9B

Book Value$-1.67

Shares Outstanding134,196,170

Financials

Revenue (TTM)1.2B

Net Income-453,436,000

EPS$-3.52

EBITDA-430,571,008

Profitability

P/E Ratio-

P/B Ratio-102.33

Return on Equity (ROE)-

Return on Assets (ROA)-18.07%

Profit Margin-38.33%

EV/EBITDA-54.69

Beta1.59

Dividend

Dividend Rate-

Dividend Yield-

Technical

RSI(14)62.17

Company Overview

Guardant Health is a precision oncology company that offers a suite of blood and tissue tests, including Guardant360 and Guardant360 CDx, to identify genetic alterations in cancer. These tests, along with data sets and software solutions like GuardantConnect, help clinicians and biopharmaceutical companies advance cancer research and therapy development. The company is a leader in liquid biopsy and comprehensive genomic profiling for cancer patients.

P/B

-102.33

Negative equity

ROE

Return on Equity

Beta

1.59

High volatility

RSI(14)

62.2

Neutral zone

AI-generated summary. Not investment advice.

Guardant Health, Inc.

Analyst Consensus

Price Information

Trading Volume

Valuation

Financials

Profitability

Dividend

Technical

Related ARK stocks